Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood–Brain Barrier in Targeted Treatment of Alzheimer’s Disease
Pharmaceutics · 01.02.2026 · 18 (2) · 192
DOI: 10.3390/pharmaceutics18020192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.02.2026. Verfasst von Hoa Le und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutics and Pharmaceutical Technology, Hanoi University of Pharmacy, Hanoi 100000, Vietnam. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
The blood–brain barrier (BBB) is a major obstacle to the development of brain-targeted drug delivery systems, restricting greater than 98% of small molecules (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmaceutics and Pharmaceutical Technology, Hanoi University of Pharmacy, Hanoi 100000, Vietnam.
- Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA 19104, USA.
- School of Pharmacy, College of Pharmacy and Health Sciences, Belmont University, Nashville, TN 37212, USA.
ORCID-Profile: Hoa Le, Giang T T Vu, Amos Abioye
Zitieren
APA
Le, H., Vu, G. T. T., Abioye, A., & Adejare, A. (2026). Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood–Brain Barrier in Targeted Treatment of Alzheimer’s Disease. Pharmaceutics, 18(2), 192. https://doi.org/10.3390/pharmaceutics18020192
Vancouver
Le H, Vu GTT, Abioye A, Adejare A. Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood–Brain Barrier in Targeted Treatment of Alzheimer’s Disease. Pharmaceutics. 2026;18(2):192. doi:10.3390/pharmaceutics18020192
BibTeX
@article{Le2026,
author = {Le, Hoa and Vu, Giang T T and Abioye, Amos and Adejare, Adeboye},
title = {Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood–Brain Barrier in Targeted Treatment of Alzheimer’s Disease},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {2},
pages = {192},
doi = {10.3390/pharmaceutics18020192}
}
EUVIMED